BREAKING NEWS Medford Police confirms one dead in plane crash near Airport Chevrolet Full Story
SEVERE WX : Air Stagnation Advisory View Alerts

Multiple sclerosis drug helps coronavirus patients recover, Phase 2 trial suggests

A drug normally prescribed to treat multiple sclerosis helped reduce the risk of severe disease from Covid-19, British researchers reported Thursday.

Posted: Nov 12, 2020 6:17 PM
Updated: Nov 12, 2020 6:18 PM

A drug normally prescribed to treat multiple sclerosis helped reduce the risk of severe disease from Covid-19, British researchers reported Thursday. But more research is needed to show whether the drug, which calms down the immune system, can really help people with severe coronavirus infections.

The researchers found British biotechnology company Synairgen's new experimental version of interferon beta-1a, repurposed to treat Covid-19, increased the odds of improvement and recovery among hospitalized Covid-19 patients in a Phase 2 trial.

"SNG001 reduced the odds of developing severe disease or dying by 79%," the researchers wrote in the journal The Lancet Respiratory Medicine.

SNG001 is an inhaled formula of interferon beta-1a, typically used to decrease inflammation and reduce the nerve damage caused by multiple sclerosis. In the trial, SNG001 was administered to 48 patients using a nebulizer while 50 patients received the placebo.

After two weeks, patients who got the daily treatment were twice as likely to get better by day 15 or 16 and more than three times as likely to improve by day 28 than those who got placebo, the researchers found. However, "there was no significant difference between treatment groups in the odds of hospital discharge or time to hospital discharge," the researchers wrote.

The researchers, from Synairgen and other institutions, found that during the two weeks of treatment, 21 patients -- or 44% -- in the SNG001 group recovered from disease compared with 11 patients -- or 22% -- in the placebo group. Then by the 28th day, 58% in the SNG001 group had recovered compared with 35% in the placebo group.

Overall, three patients died during the study and all were in the placebo group.

The researchers also found that 11 patients -- or 22% -- in the placebo group developed severe disease by day 16 compared with six patients -- or 13% -- in the SNG001 group.

The most common adverse event in the SNG001 group was headache.

"SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems to also be well tolerated in patients admitted to hospital with COVID-19," the researchers wrote in the study. "These encouraging data provide a strong rationale for larger, international studies in the context of the ongoing clinical burden of COVID-19."

The study comes with limitations, including that the number of patients in the study was small.

'There would need to be a Phase 3 trial'

"There seems to be possibly a signal here, but it's unclear how much of a signal. There's not evidence that it's a dramatic signal, like a mortality signal necessarily, and it's a small study. I think the authors of the paper sum it up best when they say there would need to be a Phase 3 trial," said Dr. Jay Finigan, pulmonologist and director of The Respiratory Centers of Excellence at National Jewish Health in Denver, who was not involved in the new study.

"All in all, we're talking relatively small numbers and there is not a signal in terms of things like discharge or mortality, although it is certainly not powered for that," he said.

Currently, the drug remdesivir is the only treatment approved by the US Food and Drug Administration for Covid-19. Some other therapies -- Eli Lilly's antibody treatment and convalescent plasma -- have received emergency use authorizations for the treatment of Covid-19. Additionally, several experimental treatments are currently being studied.

"There are certainly lots of different drugs with different delivery mechanisms. There are other inhaled drugs that are being thought about and looked at and they target different areas," Finigan said.

"There are antiviral drugs, there are drugs acting on the immune system, antibodies, there are drugs that are trying to target inflammation and some of the inflammatory mediators," he said. "All in all, unfortunately the data that have come out in this population of patients have been pretty largely consistent in that none of them have shown a mortality benefit with the exception of dexamethasone," a corticosteroid.

When it comes to SNG001, "larger randomized clinical trials" are needed, Nathan Peiffer-Smadja and Yazdan Yazdanpanah, both of Bichat-Claude Bernard Hospital in Paris, wrote in an editorial that published alongside the new study in The Lancet Respiratory Medicine.

"The safety of nebulized interferon beta-1a will be of special interest since nebulization of interferon has no marketing authorization for any indication yet," Peiffer-Smadja and Yazdanpanah wrote.

"It will also be worthwhile to investigate whether interferon beta-1a has an impact on prolonged symptoms of COVID-19, especially pulmonary symptoms," they wrote. "To optimize the antiviral effect of interferon beta, there is a greater rationale to target patients at an early stage of the disease."

Oregon Coronavirus Cases

Data is updated nightly.

Cases: 394569

Reported Deaths: 5243
CountyCasesDeaths
Multnomah60720847
Washington42359405
Marion40153516
Clackamas33040387
Lane30428361
Jackson25105363
Deschutes23795189
Umatilla15144184
Linn14859183
Douglas13523293
Josephine10278247
Yamhill9840143
Klamath9112149
Polk8325102
Benton615338
Malheur593292
Coos5768109
Columbia438056
Jefferson424366
Lincoln365852
Crook343057
Union340756
Wasco318646
Clatsop263635
Baker221833
Tillamook218046
Hood River216537
Morrow197825
Curry193939
Harney121333
Grant109116
Lake105617
Wallowa76313
Sherman1933
Gilliam1854
Wheeler1141
Unassigned00

California Coronavirus Cases

Data is updated nightly.

Cases: 5107717

Reported Deaths: 74800
CountyCasesDeaths
Los Angeles153472027244
San Diego4091824350
Riverside3892365381
San Bernardino3762805983
Orange3352965756
Sacramento1690952452
Kern1582701828
Fresno1574692270
Santa Clara1528571928
Alameda1256281512
San Joaquin1080791835
Ventura1043091192
Contra Costa1042181056
Stanislaus919641429
Tulare867391100
San Francisco57141674
San Mateo56585631
Monterey52842626
Solano47828360
Santa Barbara47523555
Merced45309671
Sonoma43349414
Placer42458473
Imperial38932776
Kings35370367
San Luis Obispo31667360
Madera26388311
Shasta26221461
Butte25608318
Santa Cruz22402224
Yolo21722261
Marin18587249
El Dorado18448168
Sutter14646186
Napa13446106
Yuba1079891
Tehama10316131
Humboldt10294119
Nevada10112105
Mendocino864999
Lassen797656
San Benito787979
Tuolumne778491
Lake7057113
Amador580067
Siskiyou479657
Glenn458536
Calaveras445788
Del Norte377942
Colusa328321
Inyo257346
Plumas19577
Mono19034
Mariposa162218
Trinity100717
Modoc7936
Sierra2190
Unassigned1560
Alpine1080
Out of CA00
Medford
Cloudy
38° wxIcon
Hi: 40° Lo: 35°
Feels Like: 38°
Brookings
Partly Cloudy
46° wxIcon
Hi: 54° Lo: 41°
Feels Like: 42°
Crater Lake
Cloudy
38° wxIcon
Hi: 38° Lo: 25°
Feels Like: 38°
Grants Pass
Cloudy
38° wxIcon
Hi: 43° Lo: 39°
Feels Like: 38°
Klamath Falls
Cloudy
30° wxIcon
Hi: 51° Lo: 29°
Feels Like: 30°
Rain arrives overnight, messy start to Monday
KDRV Radar
KDRV Fire Danger
KDRV Weather Cam

Community Events

Latest Video

Image

Medford Plane Crash

Image

Sunday, December 5th Weather

Image

Sunday, December 5th Weather

Image

Saturday, December 4th Weather

Image

Friday, December 3rd Evening Weather

Image

A year and half later, White City's only movie theatre reopens

Image

Friday, December 3rd Afternoon Weather

Image

Friday, December 3rd Morning Weather

Image

Thursday, December 2nd Evening Weather

Image

Vaccine Watch: Expo site will have pediatric Covid-19 vaccines starting Sunday